The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.

The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

Twist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from the advanced research platform.

Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.

The next wave of AI adoption is shifting from tool-builders to companies applying AI in real-world drug development. Eli Lilly leverages AI partnerships with OpenAI and Nvidia for drug discovery while expanding its weight-loss portfolio, showing strong financial growth. Twist Bioscience supplies synthetic DNA for drug testing and benefits from Amazon's new Bio Discovery platform, offering higher-risk growth potential.

ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.

The DNA computing market is projected to grow from $293.70 million in 2025 to $2.68 billion by 2032, with a 36.76% CAGR, driven by innovations in data storage, cryptography, and molecular computing technologies.

The global cell culture microcarriers market is projected to grow from USD 3.45 billion in 2025 to USD 7.2 billion by 2034, with an 8.54% CAGR, driven by advancements in biopharmaceuticals, cell therapies, and regenerative medicine research.

The DNA data storage market is expected to grow from $76 million in 2024 to $3,348 million by 2030, with a CAGR of 87.7%. The market is driven by increasing cybersecurity concerns and the need for secure, compact data storage solutions, particularly in healthcare and biotechnology sectors.

Twist Bioscience reported strong Q3 results with 18% revenue growth, achieving profitability through a one-time gain and improved operational efficiency. The company saw growth in Next Generation Sequencing and strategic product launches while managing slower Synthetic Biology segment performance.

The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.

The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.